TG Therapeutics, Inc. (TGTX) P/E Ratio History
Historical price-to-earnings valuation from 2011 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, TG Therapeutics, Inc. (TGTX) trades at a price-to-earnings ratio of 200.6x, with a stock price of $30.09 and trailing twelve-month earnings per share of $0.37.
The current P/E is 12% below its 5-year average of 228.2x. Over the past five years, TGTX's P/E has ranged from a low of 0.0x to a high of 1708.0x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, TGTX trades at a 747% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, TGTX commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TGTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Immunology and Inflammation Therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ARGXargenx SE | $47B | 60.0 | -Best | +348% |
TGTXTG Therapeutics, Inc. | $5B | 200.6 | -Best | +76% |
KNSAKiniksa Pharmaceuticals, Ltd. | $3B | 59.3 | -Best | +225% |
APLSApellis Pharmaceuticals, Inc. | $3B | 116.4 | -Best | +111% |
GLPGGalapagos N.V. | $2B | 5.9Lowest | -Best | +333% |
AUPHAurinia Pharmaceuticals Inc. | $2B | 6.8 | -Best | +5167%Best |
GYREGyre Therapeutics, Inc. | $711M | 164.8 | -Best | +104% |
RIGLRigel Pharmaceuticals, Inc. | $615M | 35.1 | -Best | +169% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $35.99 | $0.37 | 97.0x | -57% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $39.43 | $0.24 | 161.4x | -29% |
| FY2024 Q4 | $30.10 | $0.14 | 215.0x | -6% | |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $17.79 | $0.60 | 29.6x | -87% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $15.21 | $0.22 | 70.2x | -69% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $17.08 | $0.01 | 1708.0x | +649% |
| FY2011 Q4 | Sat Dec 31 2011 00:00:00 GM | $1.13 | $80.96 | 0.0x | -100% |
| FY2011 Q3 | Fri Sep 30 2011 00:00:00 GM | $6.19 | $81.22 | 0.1x | -100% |
| FY2011 Q2 | $16.88 | $82.55 | 0.2x | -100% | |
| FY2011 Q1 | $39.38 | $127.50 | 0.3x | -100% |
Average P/E for displayed period: 228.2x
See TGTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TGTX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare TGTX vs AGIO
See how TGTX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is TGTX stock overvalued or undervalued?
TGTX trades at 200.6x P/E, near its 5-year average of 228.2x. The 80th percentile ranking places valuation within normal historical bounds.
How does TGTX's valuation compare to peers?
TG Therapeutics, Inc. P/E of 200.6x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is TGTX's PEG ratio?
TGTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2025.